Literature DB >> 2069490

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.

J Bradwejn1, D Koszycki, C Shriqui.   

Abstract

We studied the action of cholecystokinin tetrapeptide (CCK-4) in patients with panic disorder and normal controls. Subjects received, in random order, one injection of CCK-4 and one injection of placebo (saline) on two separate days in a double-blind crossover design. Two doses of CCK-4, 50 and 25 micrograms, were administered to two different samples of subjects. The panic rate with 50 micrograms of CCK-4 was 100% (12/12) for patients and 47% (7/15) for controls. The panic rate with 25 micrograms of CCK-4 was 91% (10/11) for patients and 17% (2/12) for controls. Nine percent of patients compared with 0% of controls panicked with placebo. These findings concur with previous reports of a panicogenic effect of CCK-4 and suggest that patients with panic disorder are more sensitive to the panicogenic effect of the peptide than are normal controls.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069490     DOI: 10.1001/archpsyc.1991.01810310021005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  44 in total

1.  Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females.

Authors:  Emily C Bell; Glen B Baker; Christina Poag; Francois Bellavance; Janisse Khudabux; Jean-Michel Le Mellédo
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

2.  Of monkeys and men: vervets and the genetics of human-like behaviors.

Authors:  R M Palmour; J Mulligan; J J Howbert; F Ervin
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

Review 3.  Clinical uses of gut peptides.

Authors:  J Geoghegan; T N Pappas
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

Review 4.  Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y.

Authors:  Mallory E Bowers; Dennis C Choi; Kerry J Ressler
Journal:  Physiol Behav       Date:  2012-03-10

Review 5.  The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.

Authors:  Evan D Paul; Philip L Johnson; Anantha Shekhar; Christopher A Lowry
Journal:  Neurosci Biobehav Rev       Date:  2014-03-21       Impact factor: 8.989

Review 6.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

7.  Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol.

Authors:  Jarret D Morrow; Karen McManus; Glendon R Tait; Francois Bellavance; Wendy Chrapko; Nathalie Lara; Jean-Michel Le Mellédo
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

8.  The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.

Authors:  Qian Chen; Akira Nakajima; Corbin Meacham; Ya-Ping Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

Review 10.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.